Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Marketing
Meet Madrigal, which wants to be your liver's No. 1 fan
Madrigal is aiming to accomplish what has so far proven to be impossible: to bring a fatty liver drug across the FDA finish line and onto the market.
Ben Adams
Nov 15, 2023 9:40am
UPDATED: Intercept restructures as NASH hopes dashed by FDA
Jun 22, 2023 6:20pm
Intercept's NASH bid in jeopardy after bleak FDA review
May 17, 2023 1:05pm
FDA calls AdComm for Intercept's NASH drug application
Mar 10, 2023 11:18am
Intercept's Ocaliva fails its 2nd NASH trial
Sep 30, 2022 11:49am
Lipocine seeks partner for NASH asset in pivot to oral CNS drugs
Sep 26, 2022 10:50am
